CPT code 90389 designates tetanus immunoglobulin (TIg), a human plasma–derived preparation used to provide passive immunity against tetanus. TIg is clinically important for post-exposure prophylaxis in patients with certain wounds or when active immunization is inadequate. Nationally, availability and appropriate use of TIg affect acute care pathways, emergency services, and hospital formularies.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides a concise review of clinical context, payer coverage considerations, and billing and service-line implications for institutions that administer TIg.

Readers will learn the clinical purpose of CPT code 90389, typical sites of service where TIg is administered, and the operational contexts relevant to billing and claims submission. The report includes benchmark and coverage summaries from major payers where available, notes on common modifiers associated with related immunoglobulin administration, and discussion of clinical scenarios prompting TIg use. Data not available in the input are identified as such and omitted from the sections that require them.